NCT01197287View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of QAK423A in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

February 28, 2005

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

QAK423A

DRUG

QAK423A

DRUG

QAK423A

Trial Locations (1)

Unknown

Novartis Investigative Site, Berlin

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY